SEC EDGARAUG 132 min read$BWXT

Geveden Rex D sold $1.7M of BWXT

Geveden Rex D (President and CEO) sold 10,000 shares of BWX Technologies, Inc. (BWXT) at an average of $172.50 ($171.21–$174.22, $1.73M total) across 4 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Geveden Rex D

Published Aug 13, 2026, 8:10 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 13, 2026, 8:21 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$BWXT

Neutral

medium confidence

Mentioned

$BWXT

Relevance

5/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$BWXTNeutralLow

Why it matters

The newest fact is the disclosed open-market sale amount, trade dates, and confirmation that it was executed under a pre-arranged 10b5-1 plan.

Market read

Traders may monitor insider activity for sentiment, but the 10b5-1 structure reduces the likelihood of a fundamental signal.

What to watch

The article does not disclose total insider ownership changes beyond the post-transaction share count, nor whether other insiders sold or bought around the same time.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed after-hours on 2026-08-13, covering sales dated 2026-08-12.

Background

This is an SEC Form 4 insider transaction disclosure for BWX Technologies, filed by the company’s President and CEO.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$BWXTNeutralMedium confidence

Context

BWX Technologies CEO Geveden Rex D sold about $1.73M of BWXT shares via an open-market sale under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect is more about optics than new fundamentals.

Evidence & confidence

The filing provides transaction size, dates, and 10b5-1 status, but no new operating, guidance, or regulatory information.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

issuer
BWX Technologies, Inc.
Subject of the Form 4 insider sale by its President and CEO.
insider
Geveden Rex D
President and CEO who sold 10,000 shares across four trades.

Read at source ← All news

AUG 20

$BWXTLow

BWXT Names Suzanne Maddux Operations SVP to Support Nuclear Growth

BWX Technologies Inc. appointed Suzanne Maddux as senior vice president of operations to strengthen manufacturing, supply chain, and operational coordination. She will report to CEO Rex Geveden and oversee key functions, aiming to improve coordination between government and commercial operations. Maddux brings experience from Mercury Systems and RTX, with a focus on scaling operations and supporting BWXT's growth in nuclear markets.

citybiz.co2 min

AUG 19

$BWXTHighAI 9/10

BWXT wins Project Pele contract to supply U.S.'s first microreactor

BWX Technologies (BWXT) won a $300M contract to build a microreactor prototype for the U.S. Department of Defense. The company has two years to deliver the prototype to Idaho National Laboratory for testing.

ans.org1 min

AUG 11

$BWXTMedAI 9/10

BWXT (BWXT) Q2 2026 Earnings Call Transcript

BWX Technologies (NYSE:BWXT) reported Q2 2026 revenue of $901.6 million, up 18%, with adjusted EBITDA of $155.5 million (+7%) and non-GAAP EPS of $1.07 (+5%). Backlog rose to $8.4 billion (+40%). Full-year guidance was raised, including revenue to about $3.8 billion and adjusted EBITDA to $662-$672 million. BWXT also agreed to sell about 80% of its medical business for up to $800 million.

aol.com6 min

AUG 7

$BWXTMedAI 8/10

BWXT announces $800m medical sale - Nuclear Engineering International

BWX Technologies (BWXT) agreed to sell its medical business, including BWXT Medical and Kinectrics’ stable medical isotopes unit, to Nordic Capital for up to $800m. BWXT will keep a minority stake and supply isotope expertise under a long-term arrangement. The deal needs regulatory approval and is expected to close by end-2026.

neimagazine.com4 min

AUG 6

$BWXTMed

BWXT expands U.S. naval nuclear manufacturing base through PCG acquisition, targeting capacity and supply-chain gains for Navy programs

BWXT said it completed its early-July acquisition of PCG, expanding its U.S. naval nuclear manufacturing base. BWXT’s CEO Rex Geveden said most PCG revenue and backlog supports the U.S. Naval Nuclear Propulsion Program. BWXT plans integration over coming quarters, assessing which outsourced work to bring in-house and potential capital needs, with PCG focused on medium-scale components.

defence-industry.eu4 min

AUG 4